Michael Wasiura, an American Freelance journalist who lives in Russia, relates that the situation in Russia is becoming seriously frightening with regard to press freedom and democracy in general. He speaks about the constitutional referendum engineered to extend Vladimir Putins term as Russia’s president until 2036 that was postponed until July 1 and the Russian quick reopening after the Corona Crisis a skillful move because Putin’s opinion polls are falling and he wants to pretend that all is back to normal. But ist not…
He is called Wyoming and one of the biggest comedians in Spain. For the first time he gives an interview in English because he loves it: “In English, I can easier say I love you”. His real name is José Miguel Monzón and he is for sure the most popular comedian in Spain, although many people do not share his political views.
Top 100 most valuable German brands stand to lose up to 11% of brand value – over €49 billion – following devasting COVID-19 pandemic. Mercedes-Benz retains titles of Germany’s most valuable brand, brand value €58.7 billion. Germany’s fastest growing brand, RWE, jumps 32 spots in ranking following staggering 96% brand value growth. Chemicals giant BASF is nation’s strongest brand, Brand Strength Index (BSI) score 85.9 out of 100.
Over two-thirds of UK Small and medium sized enterprises (SMEs) (69%) have reported significant pressures on their cash levels. This is in large part down to businesses paying for supplies earlier than anticipated because of coronavirus-related stockpiling and fears of deeper disruptions to transport (road, air and rail) linkages. Additionally, on orders and work that has been completed, payments are being delayed. Three-quarters (74%) of business owners reported invoices due to be settled at the end of February have not been paid yet (as of 10th March 2020) and that these were unlikely to be settled before the end of March 2020.
Drug development companies could face Investigational Medical Products (IMP) and Investigational New Drug (IND) clinical supply chain and commercial product supply issues created by the UK’s departure from the EU. New rules, especially in terms of CTSM and QP services, could cost healthcare companies millions in clinical trial hold ups and potential trial failure if they are not prepared in time. Furthermore, approved drug supply and delivery will be complicated following the UK’s December 2020 full exit from Europe.“Following ratification of the UK’s “Withdrawal Agreement” there is clarity on all the forced changes the UK’s departure from Europe will involve for healthcare companies worldwide running clinical trials in the EU.